Talk:Pelareorep

Clinical trials section needs work
It's out of date. Needs updating and possibly restructuring by cancer type ? - Rod57 (talk) 15:14, 18 November 2011 (UTC)
 * Yes, I agree, it's very out-of-date. 99.235.250.152 (talk) 09:39, 19 March 2013 (UTC)

Written like an advertisement??
There is a banner claiming that this is written like an advertisement. The drug Reolysin is purely at an experimental phase right now and IT IS NOT APPROVED FOR SALE ANYWHERE IN THE WORLD, so it is certainly not being advertised. The National Cancer Institute in the USA and the National Cancer Institute in Canada are both conducting large clinical trials of this agent, and putting up roughly $40M or so of funding for these trials. So I think it is reasonable to assume that the science for this experimental agent looks encouraging (as of Oct 2012) and that the article simply reflects this fact. 99.235.250.152 (talk) 22:13, 31 October 2012 (UTC)


 * Looks ok now so have removed the advert. - Rod57 (talk) 13:27, 7 January 2016 (UTC)

move article to pelareorep
The name reolysin is no longer the proposed trade name for this drug, due to name collision with marketed pharmaceuticals. I suggest that the article be moved to its generic name pelareorep.

Requested move 6 September 2019

 * The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion. 

The result of the move request was: Moved. (non-admin closure)  D Big X ray ᗙ  15:16, 6 September 2019 (UTC)

Reolysin → pelareorep – The name "Reolysin" has been deprecated due to name collision. The innovator, Oncolytics Biotech, has stopped using the term "Reolysin" and instead is using the proposed USAN (i.e., generic) name. The innovator explains this on their web site. This is by no means controversial and under the guidelines would have been permitted and encouraged without this formal move process, but here we are. Sbelknap (talk) 14:42, 6 September 2019 (UTC)


 * The above discussion is preserved as an archive of a requested move. Please do not modify it. Subsequent comments should be made in a new section on this talk page or in a move review. No further edits should be made to this section.

"REOLYSIN®" listed at Redirects for discussion
An editor has identified a potential problem with the redirect REOLYSIN® and has thus listed it for discussion. This discussion will occur at Redirects for discussion/Log/2022 April 15 until a consensus is reached, and readers of this page are welcome to contribute to the discussion. BD2412 T 05:07, 15 April 2022 (UTC)